Invesco
AUPH icon

Invesco’s Aurinia Pharmaceuticals AUPH Stock Holding History

Invesco’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.54M Buy
208,687
+54,575
+35% +$872K ﹤0.01% 2357
2026
Q1 		$2.28M Buy
154,112
+66,679
+76% +$975K ﹤0.01% 2487
2025
Q4 		$1.39M Sell
87,433
-17,637
-17% -$250K ﹤0.01% 2765
2025
Q3 		$1.16M Sell
105,070
-13,674
-12% -$149K ﹤0.01% 2864
2025
Q2 		$1.01M Sell
118,744
-3,331
-3% -$26.7K ﹤0.01% 2842
2025
Q1 		$981K Sell
122,075
-22,037
-15% -$179K ﹤0.01% 2837
2024
Q4 		$1.29M Buy
144,112
+1,421
+1% +$11.6K ﹤0.01% 2803
2024
Q3 		$1.05M Sell
142,691
-977
-0.7% -$6.06K ﹤0.01% 2886
2024
Q2 		$820K Buy
143,668
+2,613
+2% +$13.8K ﹤0.01% 3037
2024
Q1 		$707K Sell
141,055
-3,634
-3% -$24.7K ﹤0.01% 3166
2023
Q4 		$1.3M Buy
144,689
+9,751
+7% +$80.3K ﹤0.01% 2780
2023
Q3 		$1.05M Buy
134,938
+8,511
+7% +$83.2K ﹤0.01% 2839
2023
Q2 		$1.22M Sell
126,427
-284
-0.2% -$2.95K ﹤0.01% 2812
2023
Q1 		$1.39M Buy
126,711
+44,128
+53% +$389K ﹤0.01% 2776
2022
Q4 		$357K Sell
82,583
-5,868
-7% -$34K ﹤0.01% 3436
2022
Q3 		$665K Buy
88,451
+1,985
+2% +$17.2K ﹤0.01% 3093
2022
Q2 		$868K Buy
86,466
+53,715
+164% +$600K ﹤0.01% 3042
2022
Q1 		$405K Buy
32,751
+21,340
+187% +$330K ﹤0.01% 3498
2021
Q4 		$261K Sell
11,411
-3,218
-22% -$76.3K ﹤0.01% 3672
2021
Q3 		$324K Sell
14,629
-3,342
-19% -$53K ﹤0.01% 3625
2021
Q2 		$233K Buy
+17,971
New +$229K ﹤0.01% 3733
2018
Q1 		– Sell
-10,578
Closed -$48K – 3714
2017
Q4 		$48K Buy
+10,578
New +$58.7K ﹤0.01% 3632

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco's AUPH Position: Q2 2026 in Review

Invesco increased its Aurinia Pharmaceuticals (AUPH) stake by 35% in Q2 2026, buying an estimated $872K and bringing the position to 208,687 shares worth $3.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2357.

Invesco first reported a position in AUPH in Q4 2017 and has held it in 22 quarters since. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Invesco held 208,687 shares of Aurinia Pharmaceuticals worth $3.54M as of Q2 2026.
  • Invesco bought 54,575 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $872K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2357 holding.
  • Invesco first reported a position in Aurinia Pharmaceuticals in Q4 2017 and has held it in 22 quarters since.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.